中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丙型肝炎持续病毒学应答后肝癌发生的危险因素及预测模型

许姗姗 仇丽霞 柳雅立 张晶

引用本文:
Citation:

丙型肝炎持续病毒学应答后肝癌发生的危险因素及预测模型

DOI: 10.12449/JCH240629
基金项目: 

2022年度院内中青年人才孵育项目 (BJYAYY-YN2022-02)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:许姗姗负责撰写和修改论文;仇丽霞,柳雅立负责参与文献的收集和整理;张晶负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    张晶, drzhangjing@163.com (ORCID: 0000-0002-3082-8330)

Risk factors and predictive models for liver cancer after sustained virologic response in hepatitis C

Research funding: 

Scientific Research Project of Beijing Youan Hospital, CCMU, 2022 (BJYAYY-YN2022-02)

More Information
  • 摘要: 丙型肝炎是肝癌发生的主要病因之一。随着直接抗病毒药物的应用,95%以上的患者可根除HCV,获得持续病毒学应答(SVR)。有效的抗病毒治疗可以改变丙型肝炎的自然病程,降低肝癌发生风险,但仍有一部分患者会受到年龄、性别、肝纤维化、糖尿病、肝脂肪变、饮酒和遗传因素等影响,成为肝癌高危人群。因此,如何识别和预测丙型肝炎SVR后肝癌高危人群需进一步明确与完善。本文通过系统综述丙型肝炎患者SVR后肝癌发生的危险因素和肝癌预测模型,旨在为临床识别丙型肝炎SVR后肝癌高风险人群提供依据。

     

  • [1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 29- 46. DOI: 10.3760/cma.j.cn311365-20230217-00045.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 29- 46. DOI: 10.3760/cma.j.cn311365-20230217-00045.
    [2] World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021[EB/OL]. Accountability for the global health sector strategies 2016- 2021: actions for impact, 2021, Geneva: World Health Organization.
    [3] PIÑERO F, MENDIZABAL M, RIDRUEJO E, et al. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma[J]. Liver Int, 2019, 39( 6): 1033- 1043. DOI: 10.1111/liv.14041.
    [4] EUropean Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series[J]. J Hepatol, 2020, 73( 5): 1170- 1218. DOI: 10.1016/j.jhep.2020.08.018.
    [5] Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association; Professional Committee for Hepatology, Chinese Research Hospital Association; Chinese Society of Hepatology, Chinese Medical Association, et al. Guideline for stratified screening and surveillance of primary liver cancer(2020 edition)[J]. J Clin Hepatol, 2021, 37( 2): 286- 295. DOI: 10.3969/j.issn.1001-5256.2021.02.009.

    中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国研究型医院学会肝病专业委员会, 中华医学会肝病学分会, 等. 原发性肝癌的分层筛查与监测指南(2020版)[J]. 临床肝胆病杂志, 2021, 37( 2): 286- 295. DOI: 10.3969/j.issn.1001-5256.2021.02.009.
    [6] JÍLKOVÁ ZM, SEIGNEURIN A, COPPARD C, et al. Circulating IL-13 is associated with de novo development of HCC in HCV-infected patients responding to direct-acting antivirals[J]. Cancers, 2020, 12( 12): 3820. DOI: 10.3390/cancers12123820.
    [7] HAMOIR C, HORSMANS Y, STÄRKEL P, et al. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents[J]. Acta Gastroenterol Belg, 2021, 84( 1): 25- 32. DOI: 10.51821/84.1.420.
    [8] RAVAIOLI F, CONTI F, BRILLANTI S, et al. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals[J]. Dig Liver Dis, 2018, 50( 6): 573- 579. DOI: 10.1016/j.dld.2018.02.010.
    [9] PREVEDEN T, VERES B, RUZIC M, et al. Triglyceride-Glucose Index and Hepatic Steatosis Index for the assessment of liver steatosis in HCV patients[J]. Minerva Gastroenterol, 2023, 69( 2): 254- 260. DOI: 10.23736/S2724-5985.22.03168-0.
    [10] MORADPOUR D, ENGLERT C, WAKITA T, et al. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein[J]. Virology, 1996, 222( 1): 51- 63. DOI: 10.1006/viro.1996.0397.
    [11] MORIYA K, FUJIE H, SHINTANI Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice[J]. Nat Med, 1998, 4( 9): 1065- 1067. DOI: 10.1038/2053.
    [12] NOUREDDIN M, WONG MM, TODO T, et al. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals[J]. World J Gastroenterol, 2018, 24( 11): 1269- 1277. DOI: 10.3748/wjg.v24.i11.1269.
    [13] PELEG N, ISSACHAR A, SNEH ARBIB O, et al. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response[J]. J Viral Hepat, 2019, 26( 11): 1257- 1265. DOI: 10.1111/jvh.13167.
    [14] KANWAL F, KRAMER J, ASCH SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents[J]. Gastroenterology, 2017, 153( 4): 996- 1005. e 1. DOI: 10.1053/j.gastro.2017.06.012.
    [15] DEGASPERI E, D’AMBROSIO R, IAVARONE M, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection[J]. Clin Gastroenterol Hepatol, 2019, 17( 6): 1183- 1191. e 7. DOI: 10.1016/j.cgh.2018.10.038.
    [16] LU M, LI J, RUPP LB, et al. Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma[J]. J Viral Hepat, 2016, 23( 9): 718- 729. DOI: 10.1111/jvh.12538.
    [17] KUKLA M, PIOTROWSKI D, WALUGA M, et al. Insulin resistance and its consequences in chronic hepatitis C[J]. Clin Exp Hepatol, 2015, 1( 1): 17- 29. DOI: 10.5114/ceh.2015.51375.
    [18] KARAGOZIAN R, DERDÁK Z, BAFFY G. Obesity-associated mechanisms of hepatocarcinogenesis[J]. Metabolism, 2014, 63( 5): 607- 617. DOI: 10.1016/j.metabol.2014.01.011.
    [19] TSAI PC, KUO HT, HUNG CH, et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan[J]. J Hepatol, 2023, 78( 2): 281- 292. DOI: 10.1016/j.jhep.2022.09.019.
    [20] JACOB R, PRINCE DS, KENCH C, et al. Alcohol and its associated liver carcinogenesis[J]. J Gastroenterol Hepatol, 2023, 38( 8): 1211- 1217. DOI: 10.1111/jgh.16248.
    [21] EL-SERAG HB, MASON AC. Risk factors for the rising rates of primary liver cancer in the United States[J]. Arch Intern Med, 2000, 160( 21): 3227. DOI: 10.1001/archinte.160.21.3227.
    [22] ALLEN NE, BERAL V, CASABONNE D, et al. Moderate alcohol intake and cancer incidence in women[J]. J Natl Cancer Inst, 2009, 101( 5): 296- 305. DOI: 10.1093/jnci/djn514.
    [23] TRÉPO E, PRADAT P, POTTHOFF A, et al. Impact of patatin-like phospholipase-3(rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C[J]. Hepatology, 2011, 54( 1): 60- 69. DOI: 10.1002/hep.24350.
    [24] BALASUS D, WAY M, FUSILLI C, et al. The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population[J]. Oncotarget, 2016, 7( 52): 86791- 86802. DOI: 10.18632/oncotarget.13558.
    [25] OHTA A, OGAWA E, MURATA M, et al. Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication[J]. J Med Virol, 2022, 94( 10): 5007- 5014. DOI: 10.1002/jmv.27904.
    [26] BURLONE ME, BELLAN M, BARBAGLIA MN, et al. HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment[J]. Clin J Gastroenterol, 2022, 15( 2): 301- 309. DOI: 10.1007/s12328-021-01578-1.
    [27] DEGASPERI E, GALMOZZI E, PELUSI S, et al. Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs[J]. Hepatology, 2020, 72( 6): 1912- 1923. DOI: 10.1002/hep.31500.
    [28] IOANNOU GN. HCC surveillance after SVR in patients with F3/F4 fibrosis[J]. J Hepatol, 2021, 74( 2): 458- 465. DOI: 10.1016/j.jhep.2020.10.016.
    [29] ALONSO LÓPEZ S, MANZANO ML, GEA F, et al. A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis[J]. Hepatology, 2020, 72( 6): 1924- 1934. DOI: 10.1002/hep.31588.
    [30] DAJTI E, MARASCO G, RAVAIOLI F, et al. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness[J]. JHEP Rep, 2021, 3( 3): 100289. DOI: 10.1016/j.jhepr.2021.100289.
    [31] TANI J, MORISHITA A, SAKAMOTO T, et al. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study[J]. Oncol Lett, 2020, 19( 3): 2205- 2212. DOI: 10.3892/ol.2020.11341.
    [32] SHIHA G, WAKED I, SOLIMAN R, et al. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals[J]. Liver Int, 2020, 40( 11): 2828- 2833. DOI: 10.1111/liv.14666.
    [33] IOANNOU GN, GREEN PK, BESTE LA, et al. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C[J]. J Hepatol, 2018, 69( 5): 1088- 1098. DOI: 10.1016/j.jhep.2018.07.024.
    [34] FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73( 6): 1368- 1378. DOI: 10.1016/j.jhep.2020.07.025.
    [35] QIU LX, XU SS, QIU YD, et al. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response[J]. J Viral Hepat, 2023, 30( 6): 559- 566. DOI: 10.1111/jvh.13829.
    [36] NAHON P, BAMBA-FUNCK J, LAYESE R, et al. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis[J]. J Hepatol, 2023, 78( 3): 584- 595. DOI: 10.1016/j.jhep.2022.11.003.
    [37] IOANNOU GN, TANG WJ, BESTE LA, et al. Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis[J]. JAMA Netw Open, 2020, 3( 9): e2015626. DOI: 10.1001/jamanetworkopen.2020.15626.
  • 加载中
计量
  • 文章访问数:  109
  • HTML全文浏览量:  55
  • PDF下载量:  17
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-11-12
  • 录用日期:  2023-12-01
  • 出版日期:  2024-06-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回